MarkWide Research

Sale!

Radiation Proctitis Treatment Market Analysis- Industry Size, Share, Research Report, Insights, Covid-19 Impact, Statistics, Trends, Growth and Forecast 2022-2030

Published Date: July, 2022
No of Pages: 168
Delivery Format: PDF + Excel

$2,950.00

Description of the Report

The radiation proctitis market is predicted to grow at a healthy rate of 7% between 2021 and 2031. Demand for acute radiation proctitis treatment is high, while over the coming years, the need for chronic radiation proctitis treatment is expected to increase significantly. Radiation proctitis treatment is grabbing eyeballs, with major healthcare providers and companies augmenting their R&D capacities to introduce highly advanced treatment approaches. Additionally, the rising hospitalization rate for major types of cancers is pushing the use of radiation therapy, which leads to the development of diseases like ulcerative colitis.

Manufacturers are mostly focusing on the need for chronic treatment for radiation proctitis in light of the high radiation doses administered to prostate and cervical cancer patients. The industry is promoting key strategies such as Hyperbaric Oxygen Therapy (HBOT) to tackle the growing issue and provide substantial advantages.

In its new report, consultant firm Fact. M.R. provides insights into the main factors driving demand for treatment for radiation proctitis. The study tracks sales worldwide in 20 markets that are growing rapidly and analyzes the impact COVID-19’s legislation has had on the field of healthcare generally as well as the demand for radiation proctitis treatments specifically.

Historical Trends vs. Future Growth Forecasts

With the worldwide increase in cancer incidence, patients are seeking high-quality treatment methods, including radiotherapy and chemotherapy. Numerous clinical studies were conducted earlier to prove the effectiveness of various treatments. In 2019 the market had surpassed US300 million dollars.

During the COVID-19 pandemic sweeping the world, the market saw significant advancement, specifically in regards to the increased accessibility of hyperbaric oxygen therapy (HBOT) in that it increases blood oxygen levels to reduce the possibility of inflammation in tissues and muscles. But, a slight blip was observed in the beginning due to the delay of the surgery elective.

Under Fact. Mrs projections, prospects are generally positive for 2021. Long-term prospects are also positive, with the projected CAGR of 7 percent for the next ten years and a market worth of close to US$750 million in 2031.

What is the reason for the rising Pelvic Cancer Burden driving demand for Radiation Proctitis Treatment?

According to the World Health Organization, cervical cancer is the most widespread form of pelvic cancer, with 570,000 women being diagnosed in 2018. In 2020, the number was 600,000, equivalent to 6.5 percent of female cancers. Cervical cancer is the most frequent cancer among women in over 30 lower and middle-income nations, with the majority in sub-Saharan Africa.

Thus, various therapeutic strategies are being developed to tackle the ever-growing issue. Of all the treatments treatment options, radiation therapy is most frequently used as a component of the treatment itself and also to manage its periodicity. The most frequently relied upon treatments are external beam radiation and brachytherapy.

External beam therapy uses radiation at the cancer site, however, with a greater dose of radiation. However, long-term exposure to these radiations increases the chance of developing lesions or ulcers in the pelvic region, particularly around the rectum. This leads to the development of proctitis around these areas, increasing the need for treatment in the most important areas.

What’s the reason? Hyperbaric Oxygen Therapy expected to open new possibilities?

Hyperbaric Oxygen Therapy (HBOT) is an additional treatment used to treat various diseases, including enteritis and radiation proctitis. In the course of treatment, patients can breathe 100% oxygen inside a chamber of treatment that is pressurized. The blood will be hyper oxygenated, promoting angiogenesis, collagen production, epithelialization, and improved leukocyte function.

HBOT is promoted as one of the only extremely effective treatments for patients suffering from severe radiation-induced symptoms such as cystitis and proctitis that cause bleeding. While the evidence available to date provides insufficient data about its efficacy, doctors are hopeful regarding its potential for future applications as clinical trials seek to establish concrete evidence.

The most recent HBOT trials have proven that healing reactions in patients suffering from refractory radio proctitis resulted in an overall risk decrease of 32%, with the need for other medical treatment requirements removed and the necessity for more advanced treatments largely eliminated.

Alternative non-oral Therapeutic Methods Increasing Growth Opportunities?

Apart from oral medication, notable companies and healthcare providers are offering a variety of alternatives to treatment, including laser treatments for remedial purposes to stop the continuous bleeding from the rectal. The administration of formaldehyde before surgery is also being looked at. In a clinical trial, the formalin dose of 4% was given to 20 patients with clinical and proctoscopic signs of radiation-induced proctitis.

The treatment was administered directly to the rectum with high-quality outcomes. The complete elimination of symptoms was seen in all patients. Furthermore, healthcare professionals perform the descending or transverse type of colostomy procedure for patients requiring surgery. The radiation proctitis treatment market is expanding the supply of intraperitoneal injections with formalin.

Other innovative methods like radiofrequency ablation and cold therapy (RFA) are gaining the interest of healthcare professionals. A colostomy is now a reliable and safe treatment for rectal ulcers of chronic proctitis patients. Colostomy can control bleeding from the rectal and relieves pain for patients.

Does the high cost of hyperbaric Oxygen Therapy stifle market growth?

Cost is among the main factors that affect the decision to choose a treatment. Oxygen therapy with hyperbaric is among the few options for patients suffering from severe radiation-induced symptoms. These include cystitis and proctitis, which causes bleeding.

The current state of hyperbaric oxygen therapy is costly, and consequently, people with low or middle incomes cannot pay for it, despite its significant benefits. This could be an obstacle to developing radiation therapy for the proctitis market.

Country-wise Analysis

Why is the demand for Radiation Proctitis Treatment High in the U.S.?

Based on the National Center for Biotechnology Information, The radiation therapy method is widely utilized to treat pelvic malignancies, including colorectal, prostate, and cervical cancer. Despite advances in radiation research, more than 75 percent of patients suffer from acute radiation proctitis, and up to 55% experience persistent symptoms.

There is a good chance that over 200 thousand patients undergo radiation therapy throughout the U.S. for abdominal, retroperitoneal, and pelvic cancers, such as but not only prostate, urinary, female, lymphoma, and rectal cancers. It is estimated that 1.5 two million patients suffer from radiation-induced intractable tract issues. Various gastrointestinal issues have been reported in more than 30% of cancer patients.

In the light of these developments, the potential for treating radiation proctitis throughout the country has grown dramatically. Manufacturers have a lot of opportunities in the field of hyperbaric oxygen treatment. Sechrist Industries Ltd. is a well-known manufacturer of this technology, providing products such as models 4100H, 3600H, 3300H, and 2800 pneumatic oxygen chambers. The future is bright for this technology can treat many cases of radiation proctitis, which could result in the development of numerous revenue streams.

What is the reason for Cervical Cancer Treatment Growing? U.K.s growth prospects?

It is believed that the U.K. radiation proctitis market is highly dependent on the increasing demand for treatment for cervical cancer. Based on Cancer Research U.K., between 2015 to 2017, every year, about 10% of all new cases (9 percent) were females over 75 years old. This is the 14th most frequent cancer for females and accounts for 2 percent of all cancer cases.

Through the years, massive technological advancements have brought advanced treatment methods, including radiotherapy. It accounts for 40% of total treatment for cancer in the U.K. Since it uses high-energy radiation to destroy cancerous cell lines, radiotherapy is recommended as a component of the treatment. But, this treatment comes with a variety of negative side effects.

The symptoms of diarrhea or vaginal bleeding, bladder inflammation as well as red and sore skin, and fatigue are all common. They are accompanied by other long-term effects like early menopausal changes, skin issues, and irritation to the rectum. Thus, the manufacturers are expected to expand their offerings in this area in the forecast for the long term.

Are Increasing Healthcare expenditures driving the Market in Germany? Market in Germany

According to the Economist Intelligence Unit, Germany has the highest healthcare expenditure of 11% or more of the European Union (E.U.). It is the second-highest in terms of per-capita expenditure. In 2019, the healthcare budget in Germany totaled 410.8 billion. This number increased by 19.3 billion in 2021 or 4.9 percent by 2021.

A large portion of this budget allocation has been devoted to supporting extensive cancer research and diagnosing methods. Most of these strategies employ conventional techniques, like chemotherapy, surgery or radiation therapy, targeted treatment, immunotherapy, and other advanced oncology methods to treat various cancers.

Unfortunately, the growing dependence on radiotherapy has led to an increase in the incidence of radiation-related proctitis. Thus, a variety of medications have been approved for treating ulcerative colitis, which is a typical manifestation that is caused by radiation. The most effective first-line treatment for moderate to mild ulcerative colitis comprises anti-inflammatory 5aminocsalicyclic acid (5-ASA) preparations that contain mesalazine, sulfasalazine, and.

Category-wise Insights

What is the role of chronic radiation Proctitis (CRP) treatment causing Market Expansion

Treatment for acute radiation-related proctitis has remained prevalent, attributed to the high prevalence rate (20 percent). Chronic treatment for proctitis caused by radiation is expected to grow significantly in the coming decade. Although acute side effects can manifest for up to three months following treatment, chronic side effects typically happen 3-6 months or even years post-radiation treatment.

The use of medical therapy that includes sucralfate and high amifostine has proved to be very efficient in providing an effective barrier to the immediate and long-term radiation-related effects. Furthermore, research has shown that synbiotics and macrobiotics may be utilized to alter intestinal flora and combat or treat CRP. Sun Pharmaceutical Industries is amongst the most prominent producers of amifostine drugs and drug candidates.

What is the reason why oral Therapy Radiotherapy Proctitis Therapy is Promised to remain the Most Popular?

Because of its low-risk nature, treatment with oral radiation proctitis therapy is anticipated to remain the dominant treatment. In the field of available oral treatments, anti-inflammatory medications are anticipated to be the most widely used. Balsalazide, mesalazine, and sulfa are among the most effective anti-inflammatory medications to treat radiation-related proctitis.

Several regional companies offer anti-inflammatory treatments. They include Valens Molecules (sulphasalazine), PharmaZell (balsalazide), Surya Life Sciences (mesalazine), Jiangsu RUIKE (sulphasalazine), Corden Pharma (sulphasalazine), and BEC Chemicals (mesalazine) to just some. These ingredients are extremely effective in eliminating oxygen radicals and inhibiting bacteria organisms.

The Competitive Landscape

The global radiation treatment market appears to be highly scattered, which is due to the existence of numerous local and global-level manufacturers. The primary expansion strategies are releasing new radiation treatment products, using collaborations and partnerships, scrambling for approvals from regulators, and acquiring competitors.

  • In December of 2019, Amneal Pharmaceuticals Inc. signed a definitive contract that included the acquisition of the 65.1 percent stake of AvKARE and its affiliate that operates under the name R&S Northeast, valued at more than US$300 million. The acquisition of AvKARE will allow Amneal to diversify its operations in its entire U.S. federal healthcare market.
  • In December 2020, Pfizer Inc. and Myovant Sciences announced a collaboration to develop and commercialize relugolix- a once-daily, gonadotrophin-releasing hormone (GnRH) receptor antagonist. The drug is expected to be released for women’s health and oncology throughout the U.S. and Canadian markets. The two companies will work together to create and market ORGOVYXTM to treat advanced prostate cancer and improve women’s health.
  • In April 2021, Sanofi S.A. acquired Kiadis Pharma, an early-stage biopharmaceutical company developing next-generation off-the-shelf N.K. Cell therapies. This acquisition marks a new landmark in Sanofi’sSanofis’s growing presence in immuno-oncology. Sanofi is expected to hold about 95.03 percent of the outstanding capital shares in a fully diluted manner.

Report Scope

AttributeDetails
Forecast Period2020-2030
Historical Data Available for2017-2021
Market AnalysisUS$ Mn for Value & 000 Units for Volume
Key Countries Covered
  • US
  • Canada
  • Brazil
  • Mexico
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Japan
  • China
  • India
  • Australia & New Zealand
  • GCC
  • South Africa
Key Segments Covered
  • Indication
  • Therapy
Key Companies Profiled
  • Allergan Plc.
  • Teva Pharmaceutical Industries Ltd.
  • Amneal Pharmaceuticals Inc.
  • Pfizer Inc.
  • Mylan Inc. (Viatris)
  • Sanofi SA
  • Johnson & Johnson (Johnson & Johnson Consumer Inc.)
  • Sun Pharmaceutical Industries Ltd.
  • Environmental Tectonics Corporation
  • Sechrist Industries Ltd.
Customization & PricingAvailable upon Request

Key Market Segments

  • Indication
    • Acute Radiation Proctitis
    • Chronic Proctitis from Radiation
  • Therapy
  • Oral Therapy
      • Antidiarrheal
      • Anti-inflammatory Agents
    • Other
    • Ablative Methods
    • Hyperbaric Oxygen Therapy
    • Formalin
    • Surgery

Regional Analysis

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • Italy
    • France
    • UK
    • Spain
    • Poland
    • Russia
    • The Netherlands
    • Norway
    • Czech Republic
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Indonesia
    • Malaysia
    • Thailand
    • Singapore
    • Australia & New Zealand
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Rest of South America
  • The Middle East & Africa
    • Saudi Arabia
    • UAE
    • South Africa
    • Northern Africa
    • Rest of MEA

Table of Contents

1. Preface1.1. Market Definition and Scope1.2. Market Segmentation1.3. Key Research Objectives1.4. Research Highlights2. Assumptions and Research Methodology

3. Executive Summary: Global Radiation Proctitis Treatment Market

4. Market Overview

4.1. Introduction

4.2. Overview

4.3. Market Dynamics

4.3.1. Drivers

4.3.2. Restraints

4.3.3. Opportunities

4.4. Global Radiation Proctitis Treatment Market Analysis and Forecast, 20162031

4.4.1. Market Revenue Projections (US$ Mn)

4.5. Porters Five Force Analysis

5. Market Outlook

5.1. Prevalence of Urinary Incontinence, by Region

5.2. Key Industry Events

5.3. Regulatory Scenario

5.4. Technological Advancements

5.5. Key Success Factors of Top Players

6. Global Radiation Proctitis Treatment Market Value (US$ Mn) Forecast, by Indication

6.1. Introduction & Definition

6.2. Global Radiation Proctitis Treatment Market Value Forecast, by Indication, 20162031

6.2.1. Acute Radiation Proctitis Treatment

6.2.2. Chronic Radiation Proctitis Treatment

6.3. Global Radiation Proctitis Treatment Market Attractiveness Analysis, by Indication

7. Global Radiation Proctitis Treatment Market Value (US$ Mn) Forecast, by Therapy

7.1. Introduction & Definition

7.2. Global Radiation Proctitis Treatment Market Value Forecast, by Therapy, 20162031

7.2.1. Oral Therapy

7.2.1.1. Antidiarrheals

7.2.1.2. Anti-inflammatory Agents

7.2.1.3. Others

7.2.2. Ablative Procedures

7.2.3. Hyperbaric Oxygen Therapy

7.2.4. Formalin

7.2.5. Surgery

8. Global Radiation Proctitis Treatment Market Value (US$ Mn) Forecast, by Region

8.1. Introduction

8.2. Radiation Proctitis Treatment Market Value Forecast, by Region, 20162031

8.2.1. North America

8.2.2. Europe

8.2.3. Asia Pacific

8.2.4. Latin America

8.2.5. Middle East & Africa

8.3. Global Radiation Proctitis Treatment Market Attractiveness Analysis, by Region

9. North America Radiation Proctitis Treatment Market Analysis and Forecast

9.1. Introduction

9.2. North America Radiation Proctitis Treatment Market Value Forecast, by Indication, 20162031

9.2.1. Acute Radiation Proctitis Treatment

9.2.2. Chronic Radiation Proctitis Treatment

9.3. North America Radiation Proctitis Treatment Market Value Forecast, by Therapy, 20162031

9.3.1. Oral Therapy

9.3.1.1. Antidiarrheals

9.3.1.2. Anti-inflammatory Agents

9.3.1.3. Others

9.3.2. Ablative Procedures

9.3.3. Hyperbaric Oxygen Therapy

9.3.4. Formalin

9.3.5. Surgery

9.4. North America Radiation Proctitis Treatment Market Value Forecast, by Country/Sub-region, 20162031

9.4.1. U.S.

9.4.2. Canada

9.5. North America Radiation Proctitis Treatment Market Attractiveness Analysis

9.5.1. By Indication

9.5.2. By Therapy

9.5.3. By Country/Sub-region

10. Europe Radiation Proctitis Treatment Market Analysis and Forecast

10.1. Introduction

10.2. Europe Radiation Proctitis Treatment Market Value Forecast, by Indication, 20162031

10.2.1. Acute Radiation Proctitis Treatment

10.2.2. Chronic Radiation Proctitis Treatment

10.3. Europe Radiation Proctitis Treatment Market Value Forecast, by Therapy, 20162031

10.3.1. Oral Therapy

10.3.1.1. Antidiarrheals

10.3.1.2. Anti-inflammatory Agents

10.3.1.3. Others

10.3.2. Ablative Procedures

10.3.3. Hyperbaric Oxygen Therapy

10.3.4. Formalin

10.3.5. Surgery

10.4. Europe Radiation Proctitis Treatment Market Value Forecast, by Country/Sub-region, 20162031

10.4.1. Germany

10.4.2. U.K.

10.4.3. France

10.4.4. Spain

10.4.5. Italy

10.4.6. Rest of Europe

10.5. Europe Radiation Proctitis Treatment Market Attractiveness Analysis

10.5.1. By Indication

10.5.2. By Therapy

10.5.3. By Country/Sub-region

11. Asia Pacific Radiation Proctitis Treatment Market Analysis and Forecast

11.1. Introduction

11.2. Asia Pacific Radiation Proctitis Treatment Market Value Forecast, by Indication, 20162031

11.2.1. Acute Radiation Proctitis Treatment

11.2.2. Chronic Radiation Proctitis Treatment

11.3. Asia Pacific Radiation Proctitis Treatment Market Value Forecast, by Therapy, 20162031

11.3.1. Oral Therapy

11.3.1.1. Antidiarrheals

11.3.1.2. Anti-inflammatory Agents

11.3.1.3. Others

11.3.2. Ablative Procedures

11.3.3. Hyperbaric Oxygen Therapy

11.3.4. Formalin

11.3.5. Surgery

11.4. Asia Pacific Radiation Proctitis Treatment Market Value Forecast, by Country/Sub-region, 20162031

11.4.1. Japan

11.4.2. China

11.4.3. India

11.4.4. Australia & New Zealand

11.4.5. Rest of Asia Pacific

11.5. Asia Pacific Radiation Proctitis Treatment Market Attractiveness Analysis

11.5.1. By Indication

11.5.2. By Therapy

11.5.3. By Country/Sub-region

12. Latin America Radiation Proctitis Treatment Market Analysis and Forecast

12.1. Introduction

12.2. Latin America Radiation Proctitis Treatment Market Value Forecast, by Indication, 20162031

12.2.1. Acute Radiation Proctitis Treatment

12.2.2. Chronic Radiation Proctitis Treatment

12.3. Latin America Radiation Proctitis Treatment Market Value Forecast, by Therapy, 20162031

12.3.1. Oral Therapy

12.3.2. Ablative Procedures

12.3.3. Hyperbaric Oxygen Therapy

12.3.4. Formalin

12.3.5. Surgery

12.4. Latin America Radiation Proctitis Treatment Market Value Forecast, by Country/Sub-region, 20162031

12.4.1. Brazil

12.4.2. Mexico

12.4.3. Rest of Latin America

12.5. Latin America Radiation Proctitis Treatment Market Attractiveness Analysis

12.5.1. By Indication

12.5.2. By Therapy

12.5.3. By Country/Sub-region

13. Middle East & Africa Radiation Proctitis Treatment Market Analysis and Forecast

13.1. Introduction

13.2. Middle East & Africa Radiation Proctitis Treatment Market Value Forecast, by Indication, 20162031

13.2.1. Acute Radiation Proctitis Treatment

13.2.2. Chronic Radiation Proctitis Treatment

13.3. Middle East & Africa Radiation Proctitis Treatment Market Value Forecast, by Therapy, 20162031

13.3.1. Oral Therapy

13.3.1.1. Antidiarrheals

13.3.1.2. Anti-inflammatory Agents

13.3.1.3. Others

13.3.2. Ablative Procedures

13.3.3. Hyperbaric Oxygen Therapy

13.3.4. Formalin

13.3.5. Surgery

13.4. Middle East & Africa Radiation Proctitis Treatment Market Value Forecast, by Country/Sub-region, 20162031

13.4.1. GCC Countries

13.4.2. South Africa

13.4.3. Rest of Middle East & Africa

13.5. Middle East & Africa Radiation Proctitis Treatment Market Attractiveness Analysis

13.5.1. By Indication

13.5.2. By Therapy

13.5.3. By Country/Sub-region

14. Competition Landscape

14.1. Global Radiation Proctitis Treatment Market Share Analysis, by Company, 2020

14.2. Company Profiles

14.2.1. Allergan plc

14.2.1.1. Company Description

14.2.1.2. Business Overview

14.2.1.3. Financial Overview

14.2.1.4. Strategic Overview

14.2.1.5. SWOT Analysis

14.2.2. Teva Pharmaceutical Industries Ltd.

14.2.2.1. Company Description

14.2.2.2. Business Overview

14.2.2.3. Financial Overview

14.2.2.4. Strategic Overview

14.2.2.5. SWOT Analysis

14.2.3. Amneal Pharmaceuticals, Inc.

14.2.3.1. Company Description

14.2.3.2. Business Overview

14.2.3.3. Financial Overview

14.2.3.4. Strategic Overview

14.2.3.5. SWOT Analysis

14.2.4. Pfizer, Inc.

14.2.4.1. Company Description

14.2.4.2. Business Overview

14.2.4.3. Financial Overview

14.2.4.4. Strategic Overview

14.2.4.5. SWOT Analysis

14.2.5. Mylan, Inc., (Viatris)

14.2.5.1. Company Description

14.2.5.2. Business Overview

14.2.5.3. Financial Overview

14.2.5.4. Strategic Overview

14.2.5.5. SWOT Analysis

14.2.6. Sanofi

14.2.6.1. Company Description

14.2.6.2. Business Overview

14.2.6.3. Financial Overview

14.2.6.4. Strategic Overview

14.2.6.5. SWOT Analysis

14.2.7. Johnson & Johnson (Johnson & Johnson Consumer, Inc.)

14.2.7.1. Company Description

14.2.7.2. Business Overview

14.2.7.3. Financial Overview

14.2.7.4. Strategic Overview

14.2.7.5. SWOT Analysis

14.2.8. Sun Pharmaceutical Industries Ltd.

14.2.8.1. Company Description

14.2.8.2. Business Overview

14.2.8.3. Financial Overview

14.2.8.4. Strategic Overview

14.2.8.5. SWOT Analysis

14.2.9. Environmental Tectonics Corporation

14.2.9.1. Company Description

14.2.9.2. Business Overview

14.2.9.3. Financial Overview

14.2.9.4. Strategic Overview

14.2.9.5. SWOT Analysis

14.2.10. Sechrist Industries, Inc.

14.2.10.1. Company Description

14.2.10.2. Business Overview

14.2.10.3. Financial Overview

14.2.10.4. Strategic Overview

14.2.10.5. SWOT Analysis

Know More Details About the Report

List of Tables

Table 01: Radiation Proctitis Treatment: Clinical Trial Pipeline Analysis (1/2)

Table 02: Radiation Proctitis Treatment: Clinical Trial Pipeline Analysis (2/2)

Table 03: Estimated Number of Patients with Radiation Proctitis Treatment, by Key indications, by Key Countries 2020 (1/2)

Table 04: Estimated Number of Patients with Radiation Proctitis Treatment, by Key indications, by Key Countries 2020 (2/2)

Table 05: Global Radiation Proctitis Treatment Market Value (US$ Mn) Forecast, by Indication, 20162031

Table 06: Global Radiation Proctitis Treatment Market Value (US$ Mn) Forecast, by Therapy, 20162031

Table 07: Global Radiation Proctitis Treatment Market Value (US$ Mn) Forecast, by Oral Therapy, 20162031

Table 08: Global Radiation Proctitis Treatment Market Value (US$ Mn) Forecast, by Region, 20162031

Table 09: North America Radiation Proctitis Treatment Market Value (US$ Mn) Forecast, by Country, 20162031

Table 10: North America Radiation Proctitis Treatment Market Value (US$ Mn) Forecast, by Indication, 20162031

Table 11: North America Radiation Proctitis Treatment Market Value (US$ Mn) Forecast, by Therapy, 20162031

Table 12: North America Radiation Proctitis Treatment Market Value (US$ Mn) Forecast, by Oral Therapy, 20162031

Table 13: Europe Radiation Proctitis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 20162031

Table 14: Europe Radiation Proctitis Treatment Market Value (US$ Mn) Forecast, by Indication, 20162031

Table 15: Europe Radiation Proctitis Treatment Market Value (US$ Mn) Forecast, by Therapy, 20162031

Table 16: Europe Radiation Proctitis Treatment Market Value (US$ Mn) Forecast, by Oral Therapy, 20162031

Table 17: Asia Pacific Radiation Proctitis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 20162031

Table 18: Asia Pacific Radiation Proctitis Treatment Market Value (US$ Mn) Forecast, by Indication, 20162031

Table 19: Asia Pacific Radiation Proctitis Treatment Market Value (US$ Mn) Forecast, by Therapy, 20162031

Table 20: Asia Pacific Radiation Proctitis Treatment Market Value (US$ Mn) Forecast, by Oral Therapy, 20162031

Table 21: Latin America Radiation Proctitis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 20162031

Table 22: Latin America Radiation Proctitis Treatment Market Value (US$ Mn) Forecast, by Indication, 20162031

Table 23: Latin America Radiation Proctitis Treatment Market Value (US$ Mn) Forecast, by Therapy, 20162031

Table 24: Latin America Radiation Proctitis Treatment Market Value (US$ Mn) Forecast, by Oral Therapy, 20162031

Table 25: Middle East & Africa Radiation Proctitis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 20162031

Table 26: Middle East & Africa Radiation Proctitis Treatment Market Value (US$ Mn) Forecast, by Indication, 20162031

Table 27: Middle East & Africa Radiation Proctitis Treatment Market Value (US$ Mn) Forecast, by Therapy, 20162031

Table 28: Middle East & Africa Radiation Proctitis Treatment Market Value (US$ Mn) Forecast, by Oral Therapy, 20162031

Have a report related query Speak to us directly

List of Figures

Figure 01: Global Radiation Proctitis Treatment Market Value (US$ Mn) Forecast, 20162031

Figure 02: Global Radiation Proctitis Treatment Market Value Share, by Indication, 2020

Figure 03: Global Radiation Proctitis Treatment Market Value Share, by Therapy, 2020

Figure 04: Global Radiation Proctitis Treatment Market Value Share, by Region, 2020

Figure 05: Global Radiation Proctitis Treatment Market Value Share Analysis, by Indication, 2021 and 2031

Figure 06: Global Radiation Proctitis Treatment Market Attractiveness Analysis, by Indication, 20212031

Figure 07: Global Radiation Proctitis Treatment Market Value (US$ Mn), by Acute Radiation Proctitis Treatment, 20162031

Figure 08: Global Radiation Proctitis Treatment Market Value (US$ Mn), by Chronic Radiation Proctitis Treatment, 20162031

Figure 09: Global Radiation Proctitis Treatment Market Value Share Analysis, by Therapy, 2021 and 2031

Figure 10: Global Radiation Proctitis Treatment Market Attractiveness Analysis, by Therapy, 20212031

Figure 11: Global Radiation Proctitis Treatment Market Value (US$ Mn), by Oral Therapy, 20162031

Figure 12: Global Radiation Proctitis Treatment Market Value (US$ Mn), by Ablative Procedures, 20162031

Figure 13: Global Radiation Proctitis Treatment Market Value (US$ Mn), by Hyperbaric Oxygen Therapy, 20162031

Figure 14: Global Radiation Proctitis Treatment Market Value (US$ Mn), by Formalin, 20162031

Figure 15: Global Radiation Proctitis Treatment Market Value (US$ Mn), by Surgery, 20162031

Figure 16: Global Radiation Proctitis Treatment Market Value Share Analysis, by Region, 2021 and 2031

Figure 17: Global Radiation Proctitis Treatment Market Attractiveness Analysis, by Region, 20212031

Figure 18: North America Radiation Proctitis Treatment Market Value (US$ Mn) Forecast, 20162031

Figure 19: North America Radiation Proctitis Treatment Market Value Share Analysis, by Country, 2021 and 2031

Figure 20: North America Radiation Proctitis Treatment Market Attractiv

Major Companies

  • Allergan Plc.
  • Teva Pharmaceutical Industries Ltd.
  • Amneal Pharmaceuticals Inc.
  • Pfizer Inc.
  • Mylan Inc. (Viatris)
  • Sanofi SA
  • Johnson & Johnson (Johnson & Johnson Consumer Inc.)
  • Sun Pharmaceutical Industries Ltd.
  • Environmental Tectonics Corporation
  • Sechrist Industries Ltd.

Major Segmentation

  • Indication
    • Acute Radiation Proctitis
    • Chronic Proctitis from Radiation
  • Therapy
  • Oral Therapy
      • Antidiarrheal
      • Anti-inflammatory Agents
    • Other
    • Ablative Methods
    • Hyperbaric Oxygen Therapy
    • Formalin
    • Surgery

Why Choose MWR

Quality Research

Our goal is to provide high-quality data that stimulates growth and creates a win-win situations

Unlimited User Access 

We offer Corporate User license access on all our reports in which you can share the report with your entire team without any restrictions

Free Company Inclusion 

We give you an option to include 3-4 additional company players of your choice in our report without any extra charges

Post Sale Assistance

Unlimited post sales service with an account manager dedicated to making sure that all your needs are met

Covid-19 Impact Analysis

All our research report includes latest Covid-19 Impact and its analysis

Download Free Sample PDF

444 Alaska Avenue

Suite #BAA205 Torrance, CA 90503 USA

+1 424 360 2221

24/7 Customer Support

Download Free Sample PDF